TEL AVIV, Israel, Sept. 7, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today issued a stockholder update. The Company believes in the importance of regular communication and timely information delivered to investors. To this end, mBeach is committed to share with its stockholders release regular updates on its progress.
mBeach, through its wholly owned subsidiary Skin Cancer Scanning Ltd. ("SCS") is pioneering the development and commercialization of a revolutionary and proprietary diagnostic device for the early detection and diagnosis of skin cancer. Our product, an advanced stage prototype, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers.
To date, we have successfully conducted two stages of clinical trials. The results from 128 scanned nevi demonstrated 92.4% accuracy in diagnosing non-melanoma skin cancer (NMSC). These results are significantly higher than the 75% accuracy achieved by an experienced dermatologist and 60% accuracy achieved by a general practitioner.
These initial results were gained by operating the device in the visual range (the light that we can see with an unaided eye) of the light spectrum.
We expect that further development of the devices' capabilities, into the Infra Red range, will dramatically improve results in diagnosing both Melanoma and Non Melanoma Skin Cancer.
We intend to complete the second stage development by July 2011. This will enable us to introduce into the market our SkinScan 650 diagnostic device with its full capabilities.
Our medical device, SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.
For more information on SCS, visit the company's new website at .
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
CONTACT: mBeach Software Inc. Col. Yossi Biderman, CEO info@scs-med.com